Product on VINCIT LifeSciences
Vincit LifeSciences offers world class products and services for various critical illness and diseases. At Vincit LifeSciences, our purpose is to improve the quality of life of the communities we serve.
The products that fall in the Anti-Malarial range are as follows:
Contains Artemether 80mg + Lumefantrine 480mg tab. The combination artemether/lumefantrine (trade names Falcivin-L™) is a fixed-dose combination artemisinin-based combination therapy (ACT) indicated for the treatment of acute uncomplicated Plasmodium falciparum malaria. Artemether is one of the semi-synthetic derivatives of artemisinin, and lumefantrine (also known as benflumetol and CGP 56695 during development) is purely synthetic. The combination is an effective and well-tolerated malaria treatment, providing high cure rates even in areas of multi-drug resistance.

Falcivin-L™ worked At
Malaria is caused by a protozoal parasite called Plasmodium, which is carried by mosquitoes. During a bite from an infected mosquito, the parasite passes into the body. Once inside, it lives and reproduces, resulting in the disease known as malaria.

The malaria parasites have various stages in their lifecycle within the body. After entering the bloodstream during a bite from an infected mosquito, they are carried to the liver where they reproduce. They are then released back into the bloodstream where they infect red blood cells.

In the red blood cells, the malaria parasites digest haemoglobin, the red protein within red blood cells that is responsible for carrying oxygen. When this happens, the haemoglobin is divided into two parts; haem and globin. Haem is toxic to the malaria parasites. They protect themselves from it by producing a substance that converts the toxic haem into a compound called haemozoin, which is not toxic to the parasites.

FALCIVIN-L™ (Artemether and lumefantrine) work by interfering with the ability of the malaria parasites to convert haem into haemozoin. This causes levels of the toxic haem to rise, which kills the blood stages of the malaria parasites and stops the infection from continuing.

NOTE :- The WHO Strongly recommends the use of Artemisinin-based combination therapies and more in particular the Artemether + Lumefantrine, instead of monotherapies for treatment of uncomplicated P.falciparum malaria & malignant malaria.

  • One tablet daily. Doses to be taken at diagnosis and repeated after 8, 24, 36, 48, & 60 hrs.